Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis

Immunology

Volumn 143, Issue 2, 2014, Pages 219-229

  Li, Yan Hua ^a   Yu, Jie Zhong ^a   Liu, Chun Yun ^a   Zhang, Hui ^a   Zhang, Hai Fei ^a   Yang, Wan Fang ^b   Li, Jun Lian ^b   Feng, Qian Jin ^b   Feng, Ling ^a   Zhang, Guang Xian ^c   Xiao, Bao Guo ^d   Ma, Cun Gen ^a,b  

^a SHANXI DATONG UNIVERSITY   (China)

^b SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Anti inflammatory; Experimental autoimmune encephalomyelitis; FSD C10 Fasudil derivative; Intranasal route; Neuroprotection

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ANTIINFLAMMATORY AGENT; AUTACOID; BRAIN DERIVED NEUROTROPHIC FACTOR; DRUG DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; FSD C10 COMPOUND; FSD-C10 COMPOUND; IL10 PROTEIN, MOUSE; IL2RA PROTEIN, MOUSE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; NERVE GROWTH FACTOR; NERVE PROTEIN; NEUN PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; RELA PROTEIN, MOUSE; RHO KINASE; TRANSCRIPTION FACTOR RELA;

ANIMAL; ANTI-INFLAMMATORY; ARTICLE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FSD-C10-FASUDIL DERIVATIVE; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; INTRANASAL ROUTE; METABOLISM; MOUSE; NEUROPROTECTION; SEVERITY OF ILLNESS INDEX; SPLEEN; TIME;

ANTI-INFLAMMATORY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FSD-C10-FASUDIL DERIVATIVE; INTRANASAL ROUTE; NEUROPROTECTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CD4-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SEVERITY OF ILLNESS INDEX; SPLEEN; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84908154527     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12303     Document Type: Article

References (38)

1. Patani R, Chandran S. Experimental and therapeutic opportunities for stem cells in multiple sclerosis. Int J Mol Sci 2012; 13:14470-91.
2. Yang J, Yan Y, Ciric B et al. Evaluation of bone marrow- and brain-derived neural stem cells in therapy of central nervous system autoimmunity. Am J Pathol 2010; 177:1989-2001.
3. Stamatovic SM, Keep RF, Kunkel SL et al. Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 2003; 116:4615-28.
4. Sagar D, Lamontagne A, Foss CA et al. Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J Neuroinflammation 2012; 9:245.
5. Filippini G, Del Giovane C, Vacchi L et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013; 6:CD008933.
6. Stroet A, Linker RA, Gold R. Advancing therapeutic options in multiple sclerosis with neuroprotective properties. J Neural Transm 2013; 120(Suppl. 1):S49-53.
7. Street CA, Bryan BA. Rho kinase proteins-pleiotropic modulators of cell survival and apoptosis. Anticancer Res 2011; 31:3645-57.
8. Guilluy C, Garcia-Mata R, Burridge K. Rho protein crosstalk: another social network? Trends Cell Biol 2011; 21:718-26.
9. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4:387-98.
10. Tönges L, Koch JC, Bähr M et al. ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci 2011; 4:39.
11. Bao W, Hu E, Tao L et al. Inhibition of Rho kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 2004; 61:548-58.
12. Slotta JE, Laschke MW, Menger MD et al. Rho-kinase signalling mediates endotoxin hypersensitivity after partial hepatectomy. Br J Surg 2008; 95:976-84.
13. Ding RY, Zhao DM, Zhang ZD et al. Pretreatment of Rho kinase inhibitor inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in mice. J Surg Res 2011; 171:e209-14.
14. Zhao J, Zhou D, Guo J et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir 2006; 46:421-8.
15. Lingor P, Teusch N, Schwarz K et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 2007; 103:181-9.
16. Lingor P, Tönges L, Pieper N et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008; 131:250-63.
17. Planchamp V, Bermel C, Tönges L et al. BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity. Brain 2008; 131:2606-19.
18. Sun X, Minohara M, Kikuchi H et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006; 180:126-34.
19. Hou SW, Liu CY, Li YH et al. Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. CNS Neurosci Ther 2012; 18:909-17.
20. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11:1-18.
21. Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol 2011; 40:20-35.
22. Jiang Y, Zhu J, Xu G et al. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011; 8:623-32.
23. Danielyan L, Schäfer R, von Ameln-Mayerhofer A et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009; 88:315-24.
24. Chapman CD, Frey WHII, Craft S et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2013; 30:2475-84.
25. Hanson LR, Fine JM, Svitak AL et al. Intranasal administration of CNS therapeutics to awake mice. J Vis Exp 2013; 8:e4440.
26. Nave R, Schmitt H, Popper L. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects. Drug Deliv 2013; 20:216-23.
27. Liu CY, Li YH, Yu JZ et al. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS One 2013; 8:e54841.
28. Ferber IA, Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156:5-7.
29. Lublin FD, Knobler RL, Kalman B et al. Monoclonal anti-γ interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 1993; 16:267-74.
30. Hindinger C, Bergmann CC, Hinton DR et al. IFN-γ signaling to astrocytes protects from autoimmune mediated neurological disability. PLoS One 2012; 7:e42088.
31. Berghmans N, Nuyts A, Uyttenhove C et al. Interferon-γ orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J Interferon Cytokine Res 2011; 31:575-87.
32. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003; 4:299-309.
33. Bahadur S, Pathak K. Physicochemical and physiological considerations for efficient nose-to-brain targeting. Expert Opin Drug Deliv 2012; 9:19-31.
34. Devillier P, Grassin-Delyle S, Naline E et al. Intranasal delivery of systemic drugs: a new route for opioid drugs. Therapie 2010; 65:475-81.
35. Ma CG, Zhang GX, Xiao BG et al. Suppression of EAMG by nasal administration of acetylcholine receptor. J Neuroimmunol 1995; 58:51-60.
36. Shi FD, Bai XF, Xiao BG et al. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis. J Neurol Sci 1998; 155:1-12.
37. Bai XF, Shi FD, Xiao BG et al. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA. J Neuroimmunol 1997; 80:65-75.
38. Hoekman JD, Ho RJ. Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech 2011; 12:534-43.